附件： + 热烈欢迎中情压势、 8月1日 38:本 475455 [19] 101 注：图右一为公司董事会秘书张斌与调研人员合影留念。 ...

附件： 热烈欢迎机构投资者 在临达安装 因识别 重庆有县 注：前排左七为公司董事会秘书张斌与调研人员合影留念。 ...

证券代码：002030 证券简称：达安基因 编号：2023004 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 √现场参观 □其他（） 深圳民沣私募基金 黄海山 玄甲基金 林佳义 知远投资 李梁 雷志华 深圳君茂投资 陈晓燊 深圳汇合创世投资 王兆江 朱鸿彪 深圳锦世翔投资 陈永正 西安沣相投资 杨宜洋 博锐特投资 晏小敏 北京红思客资产 杨岌 李启东 参与单位名称及 珠海富利达资产 樊继浩 人员姓名 红猫资产 陈虹桥 普弘资产 李璐瑶 粤港澳产融 雷俊宇 财通证券 邢卓 国金证券 王艳洁 张颖 国联证券 林海霖 华兴银行东莞分行 杨中伟 个人投资者 樊文星 张学聪 邓绍伟 马振亚 广州达安基因股份有限公司投资者关系活动记录表 时间 2023-07-04（下午 15:00-下午 17:30） 地点 广州市高新技术开发区科学城香山路 19 号（公司总部） 上市公司接待人 员姓名 董秘张斌、证券事务代表曾宇婷、投资者关系专员王平原 调研公司经营和产品的情况（以调研机构提问，公司高管回答 的方式展开） 问题一：了解到公司2022年报的应收账款为40个亿，一季 ...

Group 1: Financial Performance - In 2022, the company's total revenue was approximately 12 billion CNY, with over 8 billion CNY from COVID-19 testing kits and around 3 billion CNY from other routine testing kits [1] - The sales volume of routine testing products in Q1 2023 remained stable compared to the same period in 2019, despite a significant increase in shipment volume [1] - The price of some testing kits has decreased by over 30% in the past two years, impacting revenue [1] Group 2: Strategic Decisions - The company issued a price adjustment notice to respond to national policies aimed at making healthcare more affordable and accessible [2] - The decision to lower prices is also based on the company's ability to control and reduce production costs through scaled manufacturing [2] - The company has been preparing to expand its product range into the IVD (In Vitro Diagnostics) field for several years, leveraging its established subsidiaries [2] Group 3: Expansion Projects - The company is currently working on an expansion project in the Knowledge City, focusing on automated production lines for consumables and high-end IVD equipment [2] - The expansion project is aimed at enhancing the company's research and development capabilities for biochemical diagnostic reagents [2] Group 4: Profitability Metrics - The gross profit margin in Q1 2023 was better than in 2019, attributed to a more efficient operational structure and economies of scale in production [3]

附件： 普资质 国家专利 R DAAN GENE Artificate of Honor National Patents a 注：图左二为公司董事会秘书张斌与国开证券仇艳、国开证券王雯及国开证券梅凯充合影 留念。 ...

附件： 106×死見死文: 552 回回 (101 LIE 959 4/11 死亡 255 883 个 人 AR BS A 一定過这安基因殺診有限公司 "之后" 47515 国信证券广州东吴中路证券貸址部 注：前排左四为公司董事会秘书张斌与广大投资者及国信证券营业部合影留念。 ...

证券代码：002030 证券简称：达安基因 编号：2023002 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 √现场参观 □其他（） 参与单位名称及 人员姓名 国信证券梁万里、陈霭桃等以及任奕同、刘宪军等个人投资者 时间 2023-05-26（下午 15:00-下午 17:30） 地点 广州市高新技术开发区科学城香山路 19 号（公司总部） 上市公司接待人 员姓名 董秘张斌、证券事务代表曾宇婷、投资者关系专员王平原 调研公司经营和产品的情况（以调研机构提问，公司高管回答 的方式展开） 问题一：董秘您好，有留意到公司2022年年度的利润分配方案， 分红还是比较高的，每10股派发现金红利人民币17.5元。想问 问未来几年公司的分红计划是怎么样的？ 投资者关系活动 答：公司在关注自身发展的同时高度重视股东的合理投资回 主要内容介绍 报，公司在每个会计年度结束后，根据股东回报规划，制定合 理的利润分配方案。其次，大家也可以关注公司每年的年报， 达安基因从2012年开始，每三年都制定了《未来三年股东回报 规划》。目前的分红方案是在满足现金分红条件时，最近三年 ...

Financial Performance - The company's revenue for Q1 2023 was ¥341,038,087.62, a decrease of 89.86% compared to ¥3,362,176,107.47 in the same period last year[6] - Net profit attributable to shareholders was ¥36,561,352.66, down 97.82% from ¥1,679,951,294.17 year-on-year[6] - The net profit after deducting non-recurring gains and losses was ¥18,291,516.52, reflecting a decline of 98.90% compared to ¥1,667,947,149.90 in the previous year[6] - Basic and diluted earnings per share were both ¥0.0261, down 97.82% from ¥1.1970 year-on-year[6] - The weighted average return on equity was 0.32%, a significant drop from 20.51% in the previous year[6] - Operating revenue decreased by 89.86% to ¥341,038,087.62 due to reduced demand for COVID-related testing products[17] - Net profit attributable to shareholders of the parent company fell by 97.82% to ¥36,561,352.66, reflecting the decline in operating revenue[17] - Basic earnings per share decreased by 97.82% to ¥0.0261, driven by the drop in operating income[17] - The net profit for the first quarter of 2023 is CNY 37,777,912.70, compared to CNY 1,690,221,238.84 in the previous year, indicating a significant decrease[43] - The total profit before tax is CNY 49,925,181.66, significantly lower than CNY 1,992,346,057.56 from the previous year[43] - The total comprehensive income for the current period is CNY 37,408,320.51, down from CNY 1,690,303,553.03 in the previous year[43] Cash Flow and Expenses - The net cash flow from operating activities was -¥360,633,771.25, a decrease of 142.96% from ¥839,383,630.81 in the same period last year[6] - Cash flow from operating activities showed a net outflow of ¥360,633,771.25, a decrease of 142.96% compared to the previous year[17] - The cash inflow from operating activities decreased to CNY 1,241,998,318.39 from CNY 2,971,835,343.11 year-over-year[46] - The total cash outflow from investment activities was 749,122,188.26, down from 1,019,955,951.43, reflecting a reduction of about 26.5%[49] - The net cash flow from investment activities was -109,305,166.72, an improvement from -495,975,057.52 in the previous period, showing a decrease in losses by approximately 78%[49] - The net cash flow from financing activities was -34,624,291.54, compared to -26,494,506.77 in the previous period, indicating a worsening of about 30.5%[52] Assets and Liabilities - The total assets decreased to CNY 13,835,070,979.37 from CNY 14,757,073,817.98, a decline of approximately 6.3%[33] - Total current liabilities decreased to CNY 2,045,069,638.41 from CNY 2,968,742,968.32, a decline of approximately 31%[32] - Non-current liabilities decreased to CNY 136,684,654.18 from CNY 172,422,483.39, a reduction of about 20.7%[37] - The total liabilities decreased significantly, with lease liabilities down by 64.89% to ¥23,657,753.42 due to the return of leased premises[17] - The ending balance of cash and cash equivalents was 2,085,554,682.86, down from 2,481,979,285.72, representing a decrease of approximately 16%[52] Shareholder Information - The total share capital as of the last trading day before disclosure was 1,403,446,032 shares[9] - The company reported a total of 188,626 common shareholders at the end of the reporting period[60] - The largest shareholder, Guangzhou Guangyong Technology Development Co., Ltd., holds 16.63% of the shares, totaling 233,391,995 shares[60] Research and Development - Research and development expenses decreased by 36.22% to ¥76,407,740.73 due to adjustments in the R&D structure[17] - Research and development expenses amount to CNY 76,407,740.73, compared to CNY 119,790,428.09 in the previous year, reflecting a decrease in investment in innovation[43] Other Income and Financial Management - The company reported non-recurring gains of ¥10,844,623.63 from government subsidies related to normal business operations[10] - Financial expenses increased significantly by 325.16% to -¥11,690,616.19, attributed to increased interest income from time deposits[17] - Other income rose by 57.91% to ¥17,467,342.87, reflecting an increase in recognized other income compared to the same period last year[17] - Investment income turned negative at -¥13,106,754.85, primarily due to losses from joint ventures[17] - The company reported a tax expense of CNY 12,147,268.96, compared to CNY 302,124,818.72 in the previous year, indicating a reduction in tax liabilities[43] Future Outlook - The company plans to focus on expanding its market presence and developing new products and technologies in the upcoming quarters[1]

张为结：男，出生于 1971 年，1992 年参加工作，北京大学工商管理硕士。现任达安金控控股集团 有限公司董事长、本公司副总经理、财务总监。 汪洋：男，1986 年出生，硕士，高级会计师。历任中山大学达安基因股份有限公司财务部经理、 财务部总监。现任达安金控控股集团有限公司董事、广州市达瑞生物技术股份有限公司监事、本公司副 总经理、营销总监。 在股东单位任职情况 | --- | --- | --- | --- | --- | --- | |----------------------------|---------------------------|--------------------------------------|-------------------------------|-------------------------------|------------------------------| | 任职人员 姓名 | 股东单位名称 | 在股东单位担任的 职务 | 任期起始日期 | 任期终止日期 | 在股东单位是 否领取报酬津 贴 | | 薛哲强 | 广州生物工程中心有限 公司 | 董事 ...